Inclusion Criteria:

- Diagnosed with early stage MF (CTCL stage IA-IIA)

- Has at least 2 evaluable plaques

- Has been off systemic therapies for at least 4 weeks

- Has been off topical therapies for at least 2 weeks

- Has been off phototherapies for at least 2 weeks

- All skin photo-types will be included

- Subjects must have the ability to understand and the willingness to sign a written
informed consent form

- Women of child-bearing potential must agree to utilize a birth control which results
in a failure rate of less that 1% per year during the study; accepted forms of birth
control for this study include: injections such as Depo-Provera and Lunelle, implants
such as Norplant, and intra-uterine devices

- Sexually active males must agree to use a medically acceptable form of birth control
for the duration of the study and for at least 3 months after the last dose of the
study medication; appropriate birth control methods are using a condom with a
spermicide or surgical sterilization

Exclusion Criteria:

- Active history of photosensitivity (e.g. xeroderma pigmentosum, lupus erythematosus,
porphyria, severe polymorphous light eruption, solar urticaria)

- Any medical condition that could be aggravated or may cause extreme discomfort during
the study period

- Lesions only on the face, scalp or other sites that would make biopsies not
cosmetically acceptable

- Women of childbearing potential who are pregnant or attempting to become pregnant are
excluded from this study

- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to silicon phthalocyanine (Pc 4) or other agents used in this study

- Patients with uncontrolled intercurrent illness including, but not limited to ongoing
or active infection, symptomatic congestive heart failure, unstable angina pectoris,
cardiac arrhythmia, or psychiatric illness/social situations that would limit
compliance with study requirements